A Phase 1 interventional study of 10 mg d-amphetamine and 20mg d-amphetamine in Anhedonia, sponsored by The University of Texas Health Science Center, Houston. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-05.
Sponsored by The University of Texas Health Science Center, Houston · Phase 1, Interventional, and Basic science
Among 76 studies in Anhedonia with a site in United States — 24 open to participants now, 25 under way, none of them phase 3. Anhedonia · United States.
Among the 76 studies in Anhedonia with a site in United States, this one is the 36th largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 1, and was the 21st registered.
134 studies on the registry are indexed under Anhedonia; 50 are open to participants now.
Browse Anhedonia studies →24 of the 76 studies in Anhedonia with a site in United States are open now. Recruiting first, the newest first:
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
NYU Langone Health · Sites in United States
Ages 18–65
University of Pennsylvania · Sites in United States
Ages 13–17
Ksana Health · Sites in United States
Ages 13–24
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18–70 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Anhedonia studies recruiting now, 8 (19%) set no upper age limit and 33 (77%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is close to the median of 72 across 111 interventional studies indexed under Anhedonia.
Median enrollment 70 across the 67 interventional studies, 87 across the 9 observational. Of the 47 that completed or were terminated, 21 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 76 have an industry lead sponsor. The 10 most frequent:
The University of Texas Health Science Center, Houston is the lead sponsor of 899 studies on the registry; 215 are open to participants now.
Of its 174 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.
The University of Texas Health Science Center, Houston has 2 studies filed under Anhedonia — fewer than ten, so there is no comparison to draw.
13 of the studies in Anhedonia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05240352The University of Texas Health Science Center, HoustonDeveloping Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression | 2026-12-01 |
| NCT06829953University of PittsburghGet ActivE Study for At-risk Youth | 2026-12-31 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
| NCT06075771Emory UniversityDopaminergic Therapy for Anhedonia - 2 | 2027-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 76 studies in Anhedonia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the dose-response curve for therapeutic doses of d-amphetamine on tasks of motivation and reward learning in the same participants and to use d-amphetamine as a dopaminergic probe to test newer theories about the role of dopamine in reward-related decision-making.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 10 mg d-amphetamine · Drug: 20mg d-amphetamine · Drug: Placebo
Drug: 10 mg d-amphetamine · Drug: 20mg d-amphetamine · Drug: Placebo
Drug: 10 mg d-amphetamine · Drug: 20mg d-amphetamine · Drug: Placebo
Drug: 10 mg d-amphetamine · Drug: 20mg d-amphetamine · Drug: Placebo
Drug: 10 mg d-amphetamine · Drug: 20mg d-amphetamine · Drug: Placebo
Drug: 10 mg d-amphetamine · Drug: 20mg d-amphetamine · Drug: Placebo
10 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
20 mg d-amphetamine dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
Placebo dose given (double-blind) and behavioral tasks (EEfRT, PRT, ELT, CGT) administered.
Reward motivation as assessed by the Effort Expenditure for Reward Task (EEfRT)
A measure of effort-based decision-making in humans, the Effort Expenditure for Reward Task (EEfRT), will be used. The EEfRT requires participants to choose between a low-effort, low reward task vs a high-effort, high reward task. Willingness to exert effort, or reward motivation, is measured by taking the average number of hard task choices from the first 50 trials.
Time frame: about 100 minutes to 140 minutes after receiving drug at 1st, 2nd, and 3rd study session
Reward learning as assessed by the Probabilistic Reward Task (PRT)
The Probabilistic Reward Task (PRT), which uses a signal detection paradigm, will be used to measure response bias towards rewarded stimuli.
Time frame: about 100 minutes to 140 minutes after receiving drug at 1st, 2nd, and 3rd study session
Reward learning as assessed by the Effort Learning Task (ELT)
The novel Effort Learning Task (ELT) will be used, in which participants learn to associate abstract shapes with reward, loss, high effort and low effort outcomes, to examine the effect of dopaminergic stimulation on reward learning. Learning rates are determined for each symbol, and trial-wise learning curves are calculated as metrics of reward learning.
Time frame: about 100 minutes to 140 minutes after receiving drug at 1st, 2nd, and 3rd study sessions
Level of influence of counterfactual information on later decision-making, as measured by the Counterfactual Gambling Task (CGT)
Striatal dopamine is involved in signalling counterfactual information, i.e. encoding differences between the value of actual outcomes and hypothetical outcomes of alternative choices. The CGT is a gambling task used to assess the relationship between choice factors (available options, expected value, and outcomes) on self-reported measures of momentary happiness and regret. Participants complete a gambling task and are informed of their outcome and of the counterfactual outcome (i.e. hypothetical outcome had the participant selected another option). With this task, the degree to which participants make choices to avoid potential regret can be estimated.
Time frame: about 100 minutes to 140 minutes after receiving drug at 1st, 2nd, and 3rd study session
Mood state as assessed by the Profile of Mood States (POMS)
The effect of d-amphetamine on mood state will be assessed throughout sessions and will be used as a manipulation check.
Time frame: 15 minutes before receiving drug and 30, 90, 180, and 210 minutes after receiving drug at 1st, 2nd, and 3rd study sessions
Subjective effects of drug as assessed by the Drug Effects Questionnaire (DEQ)
The pharmacodynamics of d-amphetamine will be assessed throughout the study and will be used as a manipulation check.
Time frame: 15 minutes before receiving drug and 30, 90, 180, and 210 minutes after receiving drug at 1st, 2nd, and 3rd study sessions
Ran from Jan 2018 to primary completion in May 2019, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dextroamphetamine
The University of Texas Health Science Center, Houston →